Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 17, 2017. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) under the Company's 2009 Performance Share Plan.
Key Financial Metrics
The filing does not report consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details specific share transactions:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Price: $42.50 per ADS.
- Total Volume: 3,350.348 ADSs aggregated across two executives.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records an increase in notional interest in ADSs for two executives resulting from the re-investment of dividends paid on July 13, 2017.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of specific equity transactions.
Key Facts for Investor Verification
- Transaction Type: Dividend re-investment (not open market purchases).
- Executives Involved: Mr. B McNamara (CEO, GSK Consumer Healthcare) and Mr. D E Troy (SVP & General Counsel).
- Transaction Date: July 14, 2017.
- Volume Breakdown: Mr. McNamara acquired 1,065.128 ADSs; Mr. Troy acquired 2,285.22 ADSs.
- Source Limitation: This filing does not provide clear values for company-wide financial performance.